Cassava Sciences Inc $ 48.58 0 (0%)
Volume:
39,540
Avg Vol (1m):
9,378,547
Market Cap $:
1.90 Bil
Enterprise Value $:
1.87 Bil
PE Ratio:
0.00
PB Ratio:
50.60
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 76.18 | ||
| Debt-to-Equity | 0.01 | ||
| Debt-to-EBITDA | -0.06 | ||
| Piotroski F-Score | 2 | ||
| Beneish M-Score | -4.01 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| ROE % | -23.25 | ||
| ROA % | -22.03 | ||
| ROC (Joel Greenblatt) % | -3594.49 | ||
| 3-Year EBITDA Growth Rate | 50.3 | ||
| 3-Year EPS without NRI Growth Rate | 50.9 |
SAVA
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 50.6 | ||
| EV-to-EBIT | -326.01 | ||
| EV-to-EBITDA | -328 | ||
| Current Ratio | 21.46 | ||
| Quick Ratio | 21.46 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -49.1 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 50.6 | ||
| Earnings Yield (Greenblatt) % | -0.31 |